Monitoring photodynamic therapy of localized infections by bioluminescence imaging of genetically engineered bacteria.
The increasing occurrence of multi-antibiotic resistant microbes has led to the search for alternative methods of killing pathogens and treating infections. Photodynamic therapy (PDT) uses the combination of non-toxic dyes and harmless visible light to produce reactive oxygen species that can kill mammalian and microbial cells. Although the photodynamic inactivation of bacteria has been known for over a hundred years, its use to treat infections has not been much developed. This may be partly due to the difficulty of monitoring the effectiveness of PDT in animal models of infection. In order to facilitate this monitoring process, we have developed a procedure that uses bioluminescent genetically engineered bacteria and a light sensitive imaging system to allow real-time visualization of infections. When these bacteria are treated with PDT in vitro, the loss of luminescence parallels the loss of colony-forming ability. We have developed several models of infections in wounds and soft-tissue abscesses in mice that can be followed by bioluminescence imaging. The size and intensity of the infection can be sequentially monitored in a non-invasive fashion in individual mice in real-time. When photosensitizers are introduced into the infected tissue followed by illumination with red light, a light-dose dependent loss of luminescence is seen. If the bacterium is invasive, the loss of luminescence correlates with increased survival of the mice, whilst animals in control groups die of sepsis within five days. Healing of the PDT treated wounds is not impaired and may actually be improved. This approach can allow many animal models of localized infections to be accurately monitored for efficacy of treatment by PDT.
Demidova
Tatiana N
TN
Wellman Center for Photomedicine, Massachusetts General Hospital, BAR414, 40 Blossom Street, Boston, MA, USA.
Gad
Faten
F
Zahra
Touqir
T
Francis
Kevin P
KP
Hamblin
Michael R
MR
D000818:Animals; D002735:Chlorophyllides; D004927:Escherichia coli Infections / Q000188:drug therapy*; D008156:Luciferases / Q000235:genetics*; D008163:Luminescent Measurements / Q000379:methods; D051379:Mice; D010778:Photochemotherapy; D011107:Polylysine / Q000031:analogs & derivatives / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy*; D018461:Soft Tissue Infections / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D014170:Transformation, Genetic; D014946:Wound Infection / Q000188:drug therapy
D002735:Chlorophyllides; D011166:Porphyrins; D011107:Polylysine; C062985:phytochlorin; D008156:Luciferases